CIPHE – Janvier Labs Partnership: Creation of JC Discovery

In line with the opportunities created by the PACTE law and the INSERM 2025 Strategic Plan, both designed to foster technology transfer and collaborative research, the Centre d’Immunophénomique (CIPHE), a service unit of INSERM, CNRS, and Aix-Marseille University, and Janvier Labs, an industrial leader in preclinical rodent models, have joined forces to create a new spin-off company: JC Discovery (Janvier Ciphe Discovery).

The mission of JC Discovery is to harness the complementary strengths of CIPHE and Janvier Labs, combining CIPHE’s academic and scientific expertise with Janvier Labs’ nearly 60 years of experience in veterinary science, animal welfare, and model development. The partnership between CIPHE and Janvier Labs is structured and supervised by INSERM Transfert / INSERM.

JC Discovery focuses on the development and characterization of preclinical mouse and rat models, in partnership with CIPHE, in key therapeutic areas such as inflammation, autoimmunity, and immuno-oncology. These models are analyzed using advanced high-content immunophenotyping technologies.

A framework agreement between JC Discovery and INSERM–CIPHE, legally established by INSERM Transfert, defines the scope, conditions, timelines, guarantees, and pricing for services. Academic rates and CIPHE operational procedures remain unchanged, in line with its involvement in the national PHENOMIN/Celphedia and European INFRAFRONTIER infrastructures.

Janvier Labs contributes its production capabilities through assisted reproduction and custom breeding services, supporting the accelerated development and reliable reproduction of preclinical strains.

Learn more about JC Discovery: Predictive models and Innovative translational services